BCA
DRNA

Berman Capital Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Berman Capital Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
61
+57
+1,425% +$1.57K ﹤0.01% 2037
2021
Q2 		$0 Buy
+4
New +$123 ﹤0.01% 2104

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Berman Capital Advisors's DRNA Position: Q3 2021 in Review

Berman Capital Advisors increased its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 1,425% in Q3 2021, buying an estimated $1.57K and bringing the position to 61 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Berman Capital Advisors first reported a position in DRNA in Q2 2021 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Berman Capital Advisors held 61 shares of Dicerna Pharmaceuticals, Inc. worth $1K as of Q3 2021.
  • Berman Capital Advisors bought 57 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $1.57K.
  • Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2037 holding.
  • Berman Capital Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.